Literature DB >> 9251239

The alpha v beta 3 integrin "vitronectin receptor".

M A Horton1.   

Abstract

The alpha v beta 3 "vitronectin receptor" is a member of the integrin superfamily of adhesion molecules. As such, this 160/85 kDa heterodimeric protein exhibits many of the typical structural and functional features of integrins. It mediates cell adhesion to extracellular matrix by recognizing the conserved arg-gly-asp (RGD) sequence of several plasma and matrix proteins. Recently, it has also been shown that alpha v beta 3 is involved in signal transduction and cell to cell interactions. alpha v beta 3 is highly expressed in bone resorbing cells, osteoclasts, and upregulated in response to vascular damage, during angiogenesis and in certain types of malignancy. Antagonists of alpha v beta 3 are being developed for use in a variety of diseases associated with altered receptor function or level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9251239     DOI: 10.1016/s1357-2725(96)00155-0

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  107 in total

Review 1.  Regulation of osteoclast formation and function.

Authors:  L T Duong; G A Rodan
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  PECAM-1/CD31 trans-homophilic binding at the intercellular junctions is independent of its cytoplasmic domain; evidence for heterophilic interaction with integrin alphavbeta3 in Cis.

Authors:  C W Wong; G Wiedle; C Ballestrem; B Wehrle-Haller; S Etteldorf; M Bruckner; B Engelhardt; R H Gisler; B A Imhof
Journal:  Mol Biol Cell       Date:  2000-09       Impact factor: 4.138

3.  Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7.

Authors:  J C Lissitzky; J Luis; J S Munzer; S Benjannet; F Parat; M Chrétien; J Marvaldi; N G Seidah
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

Review 4.  Imaging of angiogenesis.

Authors:  Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

5.  VP7 mediates the interaction of rotaviruses with integrin alphavbeta3 through a novel integrin-binding site.

Authors:  Selene Zárate; Pedro Romero; Rafaela Espinosa; Carlos F Arias; Susana López
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 6.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

7.  Deficiency in milk fat globule-epidermal growth factor-factor 8 exacerbates organ injury and mortality in neonatal sepsis.

Authors:  Laura W Hansen; Adam Khader; Weng-Lang Yang; Asha Jacob; Tracy Chen; Jeffrey M Nicastro; Gene F Coppa; Jose M Prince; Ping Wang
Journal:  J Pediatr Surg       Date:  2016-12-30       Impact factor: 2.545

8.  Cell matrix contact modifies endothelial major histocompatibility complex class II expression in high-glucose environment.

Authors:  Markus Nickmann; Michael Saemisch; Ute Wilbert-Lampen; Thomas Nickel; Elazer R Edelman; Heiko Methe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

9.  Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Authors:  Charles N Landen; Tae-Jin Kim; Yvonne G Lin; William M Merritt; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Nicholas B Jennnings; Michael S Kinch; David Tice; Anil K Sood
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.

Authors:  Chi Soo Kang; Yunwei Chen; Hyunbeom Lee; Dijie Liu; Xiang Sun; Junghun Kweon; Michael R Lewis; Hyun-Soon Chong
Journal:  Nucl Med Biol       Date:  2014-10-20       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.